BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 21, 2011
 |  BC Week In Review  |  Company News  |  Deals

Teikoku Seiyaku, Eisai deal

Eisai exercised a 2009 option to receive exclusive, Japanese rights to develop and commercialize a transdermal formulation of Aricept donepezil to treat Alzheimer's disease (AD). Further terms were...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >